Cardiometabolic Outcomes and Mortality in Patients with Adrenal Adenomas: A Population-Based Cohort Study

Publikation: Bidrag til tidsskrift/Konferencebidrag i tidsskrift /Bidrag til avisTidsskriftartikelForskningpeer review

DOI

  • Catherine D Zhang, Endocrine Research Unit, Division of Endocrinology, Mayo Clinic
  • ,
  • Dingfeng Li, Endocrine Research Unit, Division of Endocrinology, Mayo Clinic
  • ,
  • Ravinder Jeet Kaur, Endocrine Research Unit, Division of Endocrinology, Mayo Clinic
  • ,
  • Andreas Ebbehoj
  • Sumitabh Singh, Endocrine Research Unit, Division of Endocrinology, Mayo Clinic
  • ,
  • Elizabeth J Atkinson, Mayo Clinic, Department of Health Sciences, Division of Biomedical Statistics and Informatics, Rochester, Minnesota, United States of America.
  • ,
  • Sara J Achenbach, Mayo Clinic, Department of Health Sciences, Division of Biomedical Statistics and Informatics, Rochester, Minnesota, United States of America.
  • ,
  • William F Young, Endocrine Research Unit, Division of Endocrinology, Mayo Clinic
  • ,
  • Wiebke Arlt, Birmingham Clinical Trials Unit, University of Birmingham, Birmingham, UK.
  • ,
  • Walter A Rocca
  • ,
  • Irina Bancos, Endocrine Research Unit, Division of Endocrinology, Mayo Clinic

CONTEXT: While adrenal adenomas have been linked with cardiovascular morbidity in convenience samples of patients from specialized referral centers, large-scale population-based data is lacking.

OBJECTIVE: To determine the prevalence and incidence of cardiometabolic disease and assess mortality in a population-based cohort of patients with adrenal adenomas.

DESIGN: Population-based cohort study.

SETTING: Olmsted County, Minnesota.

PATIENTS: Patients diagnosed with adrenal adenomas without overt hormone excess and age- and sex-matched referent subjects without adrenal adenomas.

MAIN OUTCOME MEASURE: Prevalence, incidence of cardiometabolic outcomes, mortality.

RESULTS: Adrenal adenomas were diagnosed in 1,004 patients (58% women, median age 63 years). At baseline, patients with adrenal adenomas were more likely to have hypertension (aOR 1.96, 95% CI 1.58-2.44), dysglycemia (aOR 1.63, 95% CI 1.33-2.00), peripheral vascular disease (aOR 1.59, 95% CI 1.32-2.06), heart failure (aOR 1.64, 95% CI 1.15-2.33), and myocardial infarction (aOR 1.50, 95% CI 1.02-2.22) compared to referent subjects. During median follow-up of 6.8 years, patients with adrenal adenomas were more likely than referent subjects to develop de novo chronic kidney disease(aHR 1.46, 95% CI 1.14-1.86), cardiac arrhythmia(aHR 1.31, 95% CI 1.08-1.58), peripheral vascular disease (aHR 1.28, 95% CI 1.05-1.55), cardiovascular events (aHR 1.33, 95% CI 1.01-1.73), and venous thromboembolic events (aHR 2.15, 95% CI 1.48-3.13). Adjusted mortality was similar between the two groups.

CONCLUSION: Adrenal adenomas are associated with an increased prevalence and incidence of adverse cardiometabolic outcomes in a population-based cohort.

OriginalsprogEngelsk
TidsskriftThe Journal of clinical endocrinology and metabolism
ISSN0021-972X
DOI
StatusE-pub ahead of print - 29 jun. 2021

Bibliografisk note

© The Author(s) 2021. Published by Oxford University Press on behalf of the Endocrine Society. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Se relationer på Aarhus Universitet Citationsformater

Aktiviteter

Projekter

ID: 219263667